Cargando…
Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression
Brain tumors are typically immunosuppressive and refractory to immunotherapies for reasons that remain poorly understood. The unbiased profiling of immune cell types in the tumor microenvironment may reveal immunologic networks affecting therapy and course of disease. Here we identify and validate t...
Autores principales: | Lu, I-Na, Dobersalske, Celia, Rauschenbach, Laurèl, Teuber-Hanselmann, Sarah, Steinbach, Anita, Ullrich, Vivien, Prasad, Shruthi, Blau, Tobias, Kebir, Sied, Siveke, Jens T., Becker, Jürgen C., Sure, Ulrich, Glas, Martin, Scheffler, Björn, Cima, Igor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222381/ https://www.ncbi.nlm.nih.gov/pubmed/34162860 http://dx.doi.org/10.1038/s41467-021-23995-z |
Ejemplares similares
-
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
por: Kebir, Sied, et al.
Publicado: (2023) -
Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022
por: Oster, Christoph, et al.
Publicado: (2023) -
Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
por: Schäfer, Niklas, et al.
Publicado: (2019) -
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma
por: Schmidt, Teresa, et al.
Publicado: (2023) -
Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
por: Glas, Martin, et al.
Publicado: (2019)